Feasibility and Benefit of Molecularly-Informed Enrollment Into Early Phase Clinical Trials for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Hematological Oncology - United Kingdom
doi 10.1002/hon.142_2630
Full Text
Open PDFAbstract
Available in full text
Date
June 1, 2019
Authors
Publisher
Wiley